store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
E64FC26 是一种有效的蛋白质二硫键异构酶 (PDI) 家族泛抑制剂,具有抗肿瘤活性,抑制 PDIA1、PDIA3、PDIA4、TXNDC5 和 PDIA6,可用于研究多发性骨髓瘤和胰腺癌。
产品描述 | E64FC26 is a potent protein disulfide isomerase (PDI) family pan-inhibitor with antitumor activity, inhibits PDIA1, PDIA3, PDIA4, TXNDC5 and PDIA6, and can be used in the study of multiple myeloma and pancreatic cancer. |
靶点活性 | anti-multiple myeloma:0.59 μM (EC50) |
体外活性 | E64FC26 exhibits anti-multiple myeloma (MM) activity with an EC50 of 0.59 μM after 24 hours of treatment in a concentration range of 0.01-100 μM[1]. E64FC26 demonstrates significant cytotoxicity in a panel of genetically diverse multiple myeloma cell lines (KMS11, OPM2, MM.1S BzR, MM.1S, SA-13, U266 BzR, ANBL6, KMS12PE, U266, 8226 DxR, 8226 BzR, KMS12BM, H929, 8226 cells)[1]. |
体内活性 |
In the NSG mouse model, E64FC26 (2 mg/kg; intraperitoneal injection; three times a week for 7 days) demonstrates anti-multiple myeloma (MM) effects, extending the median survival by 2 weeks[1]. The maximum improvement in median survival is observed with both E64FC26 and Bortezomib, leading to a 20-day extension in median survival[1].The pharmacokinetics of E64FC26 were measured in CD-1 mice. E64FC26 was administered via intravenous injection (2 mg/kg; gray trace) or oral administration (5 mg/kg; blue trace), and plasma drug concentrations were measured within 24 hours. In CD-1 mice, after a single oral dose of 5 mg/kg, the maximum concentration (Cmax) reached 400 nM with a terminal half-life of 9.5 hours, demonstrating sufficient oral bioavailability of 34%[1]. Vk*MYC transgenic mice were treated with E64FC26 (2 mg/kg, intraperitoneal injection, 3 days/week) for two consecutive weeks. E64FC26 treatment induces an immediate anti-MM response, resulting in an average reduction of 33 ± 7.9% in serum M protein for all mice[1]. |
分子量 | 340.38 |
分子式 | C19H23F3O2 |
CAS No. | 2285446-62-8 |
store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
DMSO: 80 mg/mL (235.03 mM), Sonication is recommended.
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.9379 mL | 14.6895 mL | 29.3789 mL | 73.4473 mL |
5 mM | 0.5876 mL | 2.9379 mL | 5.8758 mL | 14.6895 mL | |
10 mM | 0.2938 mL | 1.4689 mL | 2.9379 mL | 7.3447 mL | |
20 mM | 0.1469 mL | 0.7345 mL | 1.4689 mL | 3.6724 mL | |
50 mM | 0.0588 mL | 0.2938 mL | 0.5876 mL | 1.4689 mL | |
100 mM | 0.0294 mL | 0.1469 mL | 0.2938 mL | 0.7345 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
E64FC26 2285446-62-8 Others E-64FC26 Inhibitor inhibitor inhibit